MXCT (MaxCyte) Valuation Rank


MXCT MaxCyte Inc MXCT
58 GF Score
Price $1.25
GF Value $2.57
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MaxCyte Valuation Rank Related Terms

MXCT
58GF Score
MaxCyte Inc MXCT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.25 is trading 51.4% below its estimated GF Value™ of $2.57. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Valuation Rank:
  • GF Value™: $2.57 vs. price of $1.25 (51.4% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
58GF Score

Get the complete analysis for MXCT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price
$2.57
GF Value